ARTICLE | Clinical News
Exelon rivastigmine: Phase III data; marketed in EU
March 15, 1999 8:00 AM UTC
Researchers published data from a 725-patient trial in the British Medical Journal showing that patients receiving 12 mg/day of Exelon had a statistically significant improvement compared to placebo a...